DRREDDYNSEDr. Reddy's Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Sat, 7 Jun · 13:34 IST

Dr. Reddy's Laboratories Limited has informed the Exchange about Annual Report in Form 20F for the fiscal year ended March 31, 2025 filed with United States Securities and Exchange Commission.

Regulatory & Legal View source PDF

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Dr. Reddy's Laboratories has filed its Annual Report in Form 20-F with the United States Securities and Exchange Commission (US SEC) on June 7, 2025. The report covers the fiscal year ended March 31, 2025 and includes annual consolidated financial statements prepared under IFRS. The filing is a routine regulatory requirement for the company as it is listed on the New York Stock Exchange (ticker: RDY). The full report is also available on the company's website.

Likely market impact

This is a standard compliance filing with no material impact on the stock or shareholders. It reflects the company meeting its disclosure obligations as a US-listed entity and provides investors with access to IFRS-based financial statements.